Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Fresh off winning a Nobel Prize last year, and previously tackling antibodies and peptides, the University of Washington’s ...

Pseudomonas aeruginosa triggers lung transplant rejection by killing regulatory T cells, revealing new targets for AMR ...